October 10, 2017
This week's episode focuses on some of the cutting edge research being done in the Progressive MS arena. Jon's guest, Dr. Tim Coetzee, Chief Advocacy, Services & Research Officer at the National Multiple Sclerosis Society, takes us through the work of the International Progressive MS Alliance.
Jon and Tim also talk about Ocrevus — the very first drug to receive FDA approval for the treatment of Progressive MS, and what that means for future Progressive MS drug therapy.
We'll also be talking about a new research study at Duke University that will be taking full advantage of your iPhone to capture your individualized data, and we'll be letting you know how you can register for that study.
And last week, the FDA approved a higher dosage generic version of Copaxone. Generic Copaxone isn't really new…but the higher dosage is, and we'll be talking about why that might be good news for the thousands of people currently using Copaxone.
We've got news, views, interviews & breakthroughs in the MS world. Are you ready for RealTalk MS?